References

0

01

The GTN "Surveillance for Adverse Events Following Immunizations" training course has been held at: University of Cape Town in South Africa; National Pharmacovigilance Centre in Tunisia; Epidemiological Unit, Ministry of Health in Sri Lanka; and, Tarassevich Institute in Russia. For more information, see https://www.who.int/immunization_standards/vaccine_quality/gtn_aefi/en/.

02

Immunization. In: World Health Organization [website]. Geneva: World Health Organization; 2021 (https://www.who.int/news-room/facts-in-pictures/detail/immunization, accessed 10 April 2021).

03

The Global Vaccine Action Plan 2011–2020: Review and lessons learned. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/bitstream/handle/10665/329097/WHO-IVB-19.07-eng.pdf, accessed 10 April 2021).

04

Ozawa S, Clark S, Portnoy A, Grewal S, Brenzel L, Walker DG. Return on investment from childhood immunization in low- and middle-income countries, 2011–20. Health Aff (Millwood). 2016;35(2):199–207.

 

05

World Health Organization Immunization, Vaccines and Biologics (WHO/IVB) database. Database includes 193 WHO Member States. Data as of July 2009.

06

Immunization Agenda 2030: A Global Strategy To Leave No One Behind. In: World Health Organization [website]. Geneva: World Health Organization; 2020 (https://www.who.int/publications/m/item/immunization-agenda-2030-a-global-strategy-to-leave-no-one-behind, accessed 10 April 2021).

07

Chen RT et al. "The Vaccine Adverse Event Reporting System (VAERS)," Vaccine, 1994: 12(6):542–550.

08

Wilson, CB, Marcuse, EK. "Vaccine safety – vaccine benefits: science and the public's perception," Nature Reviews Immunology, 2001: 1:160–165.

09

World Health Organization (WHO). Available at: https://www.who.int/biologicals/vaccines/smallpox/en/ (Accessed 2 December 2009).

1

10

United Nations Children Fund (UNICEF). Available at: http://www.unicef.org (Accessed 2 December 2009).

100
100
101

World Health Organization (WHO). Human Papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, Geneva, 2017; 92(19):241–268.

102

World Health Organization (WHO). Human Papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, Geneva, 2017;92(19):241–268.

103

Centers for Disease Control and Prevention (CDC). Manual for the Surveillance of Vaccine-Preventable Diseases – Chapter 16: Tetanus, Atlanta (2017).

104

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for Clinical Safety assessment (E2a-e). Available on: https://www.ich.org.

105

Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. Geneva: CIOMS; 2012 (https://cioms.ch/publications/product/definitions-and-applications-of-terms-for-vaccine-pharmacovigilance/, accessed 6 Mai 2021).

106

Immunization stress-related response. A manual for program managers and health professionals to prevent, identify and respond to stress- related responses following immunization. Geneva: World Health Organization; 2019 (https://www.who.int/publications/i/item/978-92-4-151594-8, accessed 6 Mai 2021).

11

Milstien, JB. "Regulation of vaccines: strengthening the science base," Journal Public Health Policy, 2004: 25(2):173–189.

12

Baylor NW, Midthun K. "Regulation and testing of vaccines," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.

13

Duclos P, Bentsi-Enchill AD, Pfeifer D. "Vaccine safety and adverse events: lessons learnt," In: Kaufmann SHE and Lamert PH. The Grand Challenge for the Future, Basel, Switzerland: 2005: 209–229.

14

Offit PA, David RL, Gust D. "Vaccine safety," In: Plotkin S, Orenstein W, Offit PA. Vaccines, 5th edition, Philadelphia: Saunders, 2008.

15

Malaria Vaccine Initiative, PATH. Fact Sheet: Clinical trials: Steps in malaria vaccine development, Seattle, Washington.

16

US Centers for Disease Control and Prevention (CDC). "Intussusception among recipients of rotavirus vaccine – United States, 1998–1999", Morbidity and Mortality Weekly Report, 1999: 48:577–581.

17
18

Ruiz-Palacios G, Pérez-Schael I, Velázquez F, et al. "Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis," New England Journal of Medicine, 2006: 354(1):11–22.

19

Vesikari T, Matson D, Dennehy P, et al. "Safety and efficacy of a pentavalent human-bovine (wc3) reassortant rotavirus vaccine," New England Journal of Medicine, 2006: 354(1):23–33.

2

20

Chen RT, Glasser J, Rhodes P et al. "Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States," Pediatrics, 1997: 99(6):765–773.

21

US Centers for Disease Control and Prevention. Website (Clinical Immunization Safety Assessment Network section) http://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/ (Accessed 23 February 2010).

22

US Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices, February 21–22, 2007, Record of the Proceedings, Atlanta, Georgia: 2007.

23

US Centers for Disease Control and Prevention (CDC). "Prevention of rotavirus gastroenteritis among infants and children; recommendations of the Advisory Committee on Immunization Practices", Morbidity and Mortality Weekly Report, 2006: 55(RR-12).

24

Duclos P. "A global perspective on vaccine safety," Vaccine, 2004: 22:2059–2063.

25

European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine, EMEA/32706/2007: London, 19 January 2007.

26

Infant mortality and births from 2008 Immunization summary, WHO/UNICEF (The 2010 edition).

27

Uppsala Monitoring Centre. Available at: www.who-umc.org (Accessed 24 February 2010).

28

World Health Organization (WHO). "BCG vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2018; 93(8):73–96.

29

World Health Organization (WHO). "Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries", Weekly Epidemiological Record, Geneva: 2016; 91(12):145–168.

3

30

World Health Organization (WHO). "Pertussis vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2015;90(35):433–460.

31

World Health Organization (WHO). "Measles vaccines: WHO position paper", Weekly Epidemiological Record, Geneva: 2017; 92(17):205–228.

32
33

World Health Organization (WHO). "Module 4: Ensuring safe injections" In: Immunization in Practice, WHO/IVB/04.06, Geneva: WHO, 2004.

34

Black S, Eskola J, Siegrist C et al. "Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines," Lancet, Published Online October 21, 2009. DOI:10.1016/S0140- 6736(09)61877–8.

35

World Health Organization (WHO). "Causality assessment of adverse events following immunization", Weekly Epidemiological Record, Geneva: WHO, 2001: 76(12):85–89.

36

World Health Organization (WHO). Aide Mémoire: Adverse Events Following Immunization (AEFI): Causality Assessment, WHO/IVB, Geneva: 2005.

37

World Health Organization Western Pacific Regional Office (WHO/WPRO), PATH. Third Biregional Meeting on Control of Japanese Encephalitis, Manila: WHO, 2007.

38

World Health Organization (WHO). "Global Advisory Committee on Vaccine Safety: Safety of Japanese encephalitis vaccination in India", Weekly Epidemiological Record, Geneva: WHO, 2007: 82(3):23–24.

39

Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. "Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS", Expert Review Vaccines, 2009:8(6) 705–716.

4

40

Brighton Collaboration: https://brightoncollaboration.us.

 

41

World Health Organization (WHO). Available at: https://www.who.int/immunization_standards/vaccine_quality/gtn_index/en/ (Accessed 18 March 2010).

42
43

The Global Advisory Committee on Vaccine Safety (GACVS). Terms of reference. Geneva: World Health Organization; 2017 (https://www.who.int/publications/m/item/GACVS-TOR-170619, accessed 25 May 2021).

44

World Health Organization (WHO). "Global Advisory Committee on Vaccine Safety, report of meeting held 17–18 June 2009", Weekly Epidemiological Record, Geneva: 2009: 84(40):330–332.

45

Vaccine Safety Net objective and general information. Geneva: World Health Organization; 2021 (https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/vaccine-safety-net)(Accessed 17 June 2021).

46

World Health Organization (WHO). The Importance of Pharmacovigilance: safety monitoring of medicinal products, Geneva: WHO, 2002.

47
48

Uppsala Monitoring Centre (UMC). Available at: www.who-umc.org (Accessed 18 November 2009).

49

Council for International Organizations of Medical Sciences/World Health Organization (CIOMS/WHO) Working Group on Vaccine Pharmacovigilance. Vaccine Pharmacovigilance Definition. Available at: www.cioms.ch (Accessed 10 February 2010).

5

50

Global Advisory Committee on Vaccine Safety (GACVS) and World Health Organization Secretariat. "Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS," Expert Review Vaccines, 2009: 8(6),705–716.

51

Zanardi LR, Haber P, Mootrey GT, Niu MT, Wharton M and the VAERS Working Group. "Intussusception Among Recipients of Rotavirus Vaccine: Reports to the Vaccine Adverse Event Reporting System" Pediatrics, 2001: 107;e97 DOI:10.1542/peds.107.6.e97.

52

Robert Pless, Public Health Agency of Canada. (Personal communication January 2010).

53

World Health Organization (WHO). Available at: https://www.who.int/immunization_standards/national_regulatory_authorities/strengthening/en/ (Accessed 1 March 2009).

54

Burgess DC, Burgess MA, Leask J. The MMR vaccination and autism controversy in United Kingdom 1998–2005: inevitable community outrage or a failure of risk communication? Vaccine 24, 3912–3928 (2006).

55

World Health Organizaton Global Training Network. "Similarities and differences between vaccines and medicines," In: WHO Global Training Network: Adverse events following immunization (AEFI), Geneva: WHO, 2009.

56

World Health Organization (WHO). "Module 3: The cold chain" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.

57

World Health Organization (WHO). "Module 4: Ensuring safe injections" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.

58

World Health Organization (WHO). "Module 6: Holding an immunization session" In: Immunization in Practice, Geneva: WHO/IVB/04/06, 2004.

59

Gold R. Your Child's Best Shot: A parent's guide to vaccination 3rd edition, Canadian Paediatric Society, Canada, 2006.

6

60

Council for International Organizations of Medical Sciences (CIOMS). Guidelines for Preparing Core Clinical Safety Information on Drugs – Report of CIOMS Working Group III, Geneva: WHO, 1995.

61

World Health Organization (WHO). "Rotavirus vaccines: an update" Weekly Epidemiological Record, Geneva: 2009:84(51–52):533–538.

62

World Health Organization (WHO). "Yellow fever vaccine: WHO position paper" Weekly Epidemiological Record, Geneva: 2013;88(27):269–284.

63

World Health Organization (WHO). "Hepatitis B vaccines: WHO position paper", Weekly Epidemiological Record, Geneva: 2017;92(27):369–392.

64
65

World Health Organization (WHO). "WHO position paper on Haemophilus influenzae type b conjugate vaccines", Weekly Epidemiological Record, Geneva: 2013;88(39):413–428.

66

World Health Organization (WHO). "Pneumococcal conjugate vaccine for childhood immunization – WHO position paper", Weekly Epidemiological Record, Geneva: 2019;94(8):85–104.

67

Meningitis vaccine project. Available at: www.meningvax.org (Accessed 1 January 2010).

68

World Health Organization (WHO). "Tetanus vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2017;92(6):53–76.

69

World Health Organization (WHO). "Diphtheria vaccine: WHO position paper", Weekly Epidemiological Record, Geneva: 2017;92(31):417–436.

7

70

Adapted from Martin Friede.

71

Brief overview of anaphylaxis as AEFI and practical guidance on its identification, case management and response in a primary care setting. Geneva: World Health Organization; 2021 (https://www.who.int/publications/m/item/anaphylaxis-guidance, accessed 16 June 2021).

72

World Health Organization (WHO). "Revised BCG vaccination guidelines for infants at risk for HIV infection", Weekly Epidemiological Record, Geneva: 2007:82(21):193–196.

73

World Health Organization (WHO). "Influenza Vaccines WHO Position Paper", Weekly Epidemiological Record, No. 33, 19 August 2005.

74

World Health Organization (WHO). Website (Vaccine-preventable diseases section). Available at: https://www.who.int/immunization/diseases/MNTE_initiative/en/ (Accessed 19 May 2010).

75

World Health Organization (WHO). Website (Maternal and Neonatal Tetanus (MNT) elimination). Available at: https://www.who.int/immunization/diseases/MNTE_initiative/en/ (Accessed January 2012)

76

D. Baxter. (2007). Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond) 57 (8): 552–556. doi: 10.1093/occmed/kqm11.

77

World Health Organization (WHO). Website (Information related to influenza immunization). Available at: https://www.who.int/influenza/vaccines/SAGE_information/en/ (Accessed 25 May 2012).

78
79

WHO WER 2007; 82:17–24 and WER 2007; 82:181–96.

8

80

Siegrist CA, Lewis EM, Eskola J, Evans S, Black S. "Human Papilloma Virus Immunization in Adolescent and Young Adults: A Cohort Study to Illustrate What Events Might be Mistaken for Adverse Reactions." The Pediatric Infectious Disease Journal. Volume 26, Number 11, November 2007.

81
82
83

Uppsala Monitoring Center (UMC): https://www.who-umc.org

84

Global Advisory Committee on Vaccine Safety (GACVS): https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/

85

Brighton Collaboration: https://brightoncollaboration.us.

86
87
88

Global Learning Opportunities for Vaccine Quality:
https://www.who.int/immunization_standards/vaccine_quality/gtn_index/en/

89

9

90

More about the History of Anti-vaccination Movements: College of Physicians of Philadelphia: The history of vaccines: https://www.historyofvaccines.org/content/articles/history-anti-vaccination-movements

91

Haut Conseil de la Santé Publique (HCSP). Vaccinations des personnes immunodéprimées ou aspléniques (2012).

92

The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine, 2007; 25(31):5671—5674. https://pubmed.ncbi.nlm.nih.gov/17400339/

93

Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine, 2007; 25(31):5771—5792. https://pubmed.ncbi.nlm.nih.gov/17570566/

94
95
96
97
98

Guillard-Maure C, Elango V, Black S, Perez-Vilar S, Castro JL, Bravo-Alcantara P et al. Operational lessons learned in conducting a multi-country collaboration for vaccine safety signal verification and hypothesis testing: The global vaccine safety multi country collaboration initiative. Vaccine. 2018;36(3):355–362.

99

World Health Organization (WHO). Human Papillomavirus vaccines: WHO position paper. Weekly Epidemiological Record, Geneva, 2017;92(19):241–268